【AI详解】Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics.

文献信息

一句话小结

本研究生成了临床注释的食管腺癌类器官培养物，成功重现了原发肿瘤的形态和遗传特征，揭示了肿瘤的克隆结构及其演变过程。此类器官不仅为探索食管腺癌的生物学机制提供了新模型，也为精准治疗的前临床研究奠定了基础。

在麦伴科研 (maltsci.com) 搜索更多文献

食管腺癌 · 类器官培养 · 克隆选择 · 精准治疗 · 多克隆性

摘要

食管腺癌（EAC）的发病率正在上升，而五年生存率仍然低于15%。缺乏实验模型阻碍了相关研究的进展。我们已生成临床注释的EAC类器官培养物，这些培养物重现了原发肿瘤的形态、基因组和转录组特征，包括点突变、拷贝数改变和突变特征。类器官培养物的核型分析确认了多克隆性，反映了原发肿瘤的克隆结构。此外，亚克隆经历了与驱动基因状态相关的克隆选择。中等通量药物敏感性测试显示了靶向受体酪氨酸激酶及其下游介质的潜力。EAC类器官培养物为克隆演化和精准治疗的前临床研究提供了工具。

英文摘要

Esophageal adenocarcinoma (EAC) incidence is increasing while 5-year survival rates remain less than 15%. A lack of experimental models has hampered progress. We have generated clinically annotated EAC organoid cultures that recapitulate the morphology, genomic, and transcriptomic landscape of the primary tumor including point mutations, copy number alterations, and mutational signatures. Karyotyping of organoid cultures has confirmed polyclonality reflecting the clonal architecture of the primary tumor. Furthermore, subclones underwent clonal selection associated with driver gene status. Medium throughput drug sensitivity testing demonstrates the potential of targeting receptor tyrosine kinases and downstream mediators. EAC organoid cultures provide a pre-clinical tool for studies of clonal evolution and precision therapeutics.

麦伴智能科研服务

主要研究问题

1. 在食管腺癌的类器官培养中，如何进一步验证不同亚克隆的功能特性？
2. 针对食管腺癌的精准治疗，类器官模型如何帮助识别新的药物靶点？
3. 食管腺癌类器官培养在临床试验中的应用前景如何，特别是在个体化治疗方面？
4. 类器官培养如何提高我们对食管腺癌发生机制的理解，尤其是其多克隆性特征？
5. 在药物敏感性测试中，类器官模型如何模拟患者对治疗的反应，以便优化治疗方案？

核心洞察

研究背景和目的

食管腺癌（EAC）是全球第八大常见癌症，其发病率不断上升，但五年生存率仍低于15%。由于缺乏有效的实验模型，研究进展受到限制。本文旨在建立临床注释的EAC类器官培养，以重现原发肿瘤的形态学、基因组和转录组特征，并评估其在克隆演化和精准治疗研究中的应用。

主要方法/材料/实验设计

本研究采用以下方法生成和分析EAC类器官：

1. 样本收集：从接受食管切除术的患者处收集新鲜EAC组织样本，进行类器官培养。
2. 类器官培养：通过特定培养基和基质，建立EAC类器官，成功率为31%（10/32样本）。
3. 表型和分子特征分析：
   • 组织学评估：通过免疫组化检测表皮特异性标记物，确认类器官的上皮来源。
   • 基因组分析：进行全基因组测序，评估肿瘤驱动基因、突变和拷贝数变化。
   • 克隆性分析：通过光谱核型分析（SKY）评估类器官的多克隆性和克隆演化。
4. 药物敏感性测试：对24种抗癌药物进行中等通量药物敏感性测试，以评估类器官对不同治疗的反应。

关键结果和发现

1. 类器官建立：成功建立10个EAC类器官，其中90%的类器官能够长期生长（超过6个月）。
2. 组织学特征：类器官表现出与原发肿瘤相似的组织学特征，主要突变和基因组改变得到保留。
3. 克隆性分析：类器官保持了肿瘤的多克隆性，且在培养过程中显示出克隆动态变化。
4. 药物敏感性：类器官对多种药物的敏感性表现出显著异质性，其中一些类器官对特定靶向药物表现出较高的敏感性。

主要结论/意义/创新性

本研究成功建立了EAC类器官模型，提供了一个生理相关的实验工具，用于研究肿瘤的克隆演化和精准治疗。这些类器官不仅重现了原发肿瘤的特征，还为评估新疗法的有效性提供了平台，具有重要的临床转化潜力。

研究局限性和未来方向

尽管类器官模型展示了良好的生物学特性，但仍存在以下局限性：

• 样本量有限：当前研究的样本数量较少，未来需要扩展样本库以增强结果的普遍性。
• 环境差异：类器官培养的微环境与原发肿瘤存在差异，可能影响某些基因表达和药物反应。

未来的研究方向包括：

• 扩大类器官库，进行更大规模的药物筛选。
• 探索类器官与肿瘤微环境的相互作用，进一步理解肿瘤的生物学特性。

参考文献

1. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. - Charlotte Soneson;Michael I Love;Mark D Robinson - F1000Research (2015)
2. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. - Peter Eirew;Adi Steif;Jaswinder Khattra;Gavin Ha;Damian Yap;Hossein Farahani;Karen Gelmon;Stephen Chia;Colin Mar;Adrian Wan;Emma Laks;Justina Biele;Karey Shumansky;Jamie Rosner;Andrew McPherson;Cydney Nielsen;Andrew J L Roth;Calvin Lefebvre;Ali Bashashati;Camila de Souza;Celia Siu;Radhouane Aniba;Jazmine Brimhall;Arusha Oloumi;Tomo Osako;Alejandra Bruna;Jose L Sandoval;Teresa Algara;Wendy Greenwood;Kaston Leung;Hongwei Cheng;Hui Xue;Yuzhuo Wang;Dong Lin;Andrew J Mungall;Richard Moore;Yongjun Zhao;Julie Lorette;Long Nguyen;David Huntsman;Connie J Eaves;Carl Hansen;Marco A Marra;Carlos Caldas;Sohrab P Shah;Samuel Aparicio - Nature (2015)
3. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. - Niccolo Bolli;Hervé Avet-Loiseau;David C Wedge;Peter Van Loo;Ludmil B Alexandrov;Inigo Martincorena;Kevin J Dawson;Francesco Iorio;Serena Nik-Zainal;Graham R Bignell;Jonathan W Hinton;Yilong Li;Jose M C Tubio;Stuart McLaren;Sarah O’ Meara;Adam P Butler;Jon W Teague;Laura Mudie;Elizabeth Anderson;Naim Rashid;Yu-Tzu Tai;Masood A Shammas;Adam S Sperling;Mariateresa Fulciniti;Paul G Richardson;Giovanni Parmigiani;Florence Magrangeas;Stephane Minvielle;Philippe Moreau;Michel Attal;Thierry Facon;P Andrew Futreal;Kenneth C Anderson;Peter J Campbell;Nikhil C Munshi - Nature communications (2014)
4. Signatures of mutational processes in human cancer. - Ludmil B Alexandrov;Serena Nik-Zainal;David C Wedge;Samuel A J R Aparicio;Sam Behjati;Andrew V Biankin;Graham R Bignell;Niccolò Bolli;Ake Borg;Anne-Lise Børresen-Dale;Sandrine Boyault;Birgit Burkhardt;Adam P Butler;Carlos Caldas;Helen R Davies;Christine Desmedt;Roland Eils;Jórunn Erla Eyfjörd;John A Foekens;Mel Greaves;Fumie Hosoda;Barbara Hutter;Tomislav Ilicic;Sandrine Imbeaud;Marcin Imielinski;Marcin Imielinsk;Natalie Jäger;David T W Jones;David Jones;Stian Knappskog;Marcel Kool;Sunil R Lakhani;Carlos López-Otín;Sancha Martin;Nikhil C Munshi;Hiromi Nakamura;Paul A Northcott;Marina Pajic;Elli Papaemmanuil;Angelo Paradiso;John V Pearson;Xose S Puente;Keiran Raine;Manasa Ramakrishna;Andrea L Richardson;Julia Richter;Philip Rosenstiel;Matthias Schlesner;Ton N Schumacher;Paul N Span;Jon W Teague;Yasushi Totoki;Andrew N J Tutt;Rafael Valdés-Mas;Marit M van Buuren;Laura van ’t Veer;Anne Vincent-Salomon;Nicola Waddell;Lucy R Yates; ; ; ; ;Jessica Zucman-Rossi;P Andrew Futreal;Ultan McDermott;Peter Lichter;Matthew Meyerson;Sean M Grimmond;Reiner Siebert;Elías Campo;Tatsuhiro Shibata;Stefan M Pfister;Peter J Campbell;Michael R Stratton - Nature (2013)
5. Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. - Nick Barker;Meritxell Huch;Pekka Kujala;Marc van de Wetering;Hugo J Snippert;Johan H van Es;Toshiro Sato;Daniel E Stange;Harry Begthel;Maaike van den Born;Esther Danenberg;Stieneke van den Brink;Jeroen Korving;Arie Abo;Peter J Peters;Nick Wright;Richard Poulsom;Hans Clevers - Cell stem cell (2010)
6. Organoid cultures derived from patients with advanced prostate cancer. - Dong Gao;Ian Vela;Andrea Sboner;Phillip J Iaquinta;Wouter R Karthaus;Anuradha Gopalan;Catherine Dowling;Jackline N Wanjala;Eva A Undvall;Vivek K Arora;John Wongvipat;Myriam Kossai;Sinan Ramazanoglu;Luendreo P Barboza;Wei Di;Zhen Cao;Qi Fan Zhang;Inna Sirota;Leili Ran;Theresa Y MacDonald;Himisha Beltran;Juan-Miguel Mosquera;Karim A Touijer;Peter T Scardino;Vincent P Laudone;Kristen R Curtis;Dana E Rathkopf;Michael J Morris;Daniel C Danila;Susan F Slovin;Stephen B Solomon;James A Eastham;Ping Chi;Brett Carver;Mark A Rubin;Howard I Scher;Hans Clevers;Charles L Sawyers;Yu Chen - Cell (2014)
7. Fast and accurate short read alignment with Burrows-Wheeler transform. - Heng Li;Richard Durbin - Bioinformatics (Oxford, England) (2009)
8. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. - Austin M Dulak;Petar Stojanov;Shouyong Peng;Michael S Lawrence;Cameron Fox;Chip Stewart;Santhoshi Bandla;Yu Imamura;Steven E Schumacher;Erica Shefler;Aaron McKenna;Scott L Carter;Kristian Cibulskis;Andrey Sivachenko;Gordon Saksena;Douglas Voet;Alex H Ramos;Daniel Auclair;Kristin Thompson;Carrie Sougnez;Robert C Onofrio;Candace Guiducci;Rameen Beroukhim;Zhongren Zhou;Lin Lin;Jules Lin;Rishindra Reddy;Andrew Chang;Rodney Landrenau;Arjun Pennathur;Shuji Ogino;James D Luketich;Todd R Golub;Stacey B Gabriel;Eric S Lander;David G Beer;Tony E Godfrey;Gad Getz;Adam J Bass - Nature genetics (2013)
9. Whole-genome sequencing of nine esophageal adenocarcinoma cell lines. - Gianmarco Contino;Matthew D Eldridge;Maria Secrier;Lawrence Bower;Rachael Fels Elliott;Jamie Weaver;Andy G Lynch;Paul A W Edwards;Rebecca C Fitzgerald - F1000Research (2016)
10. Endothelial RSPO3 Controls Vascular Stability and Pruning through Non-canonical WNT/Ca(2+)/NFAT Signaling. - Beate Scholz;Claudia Korn;Jessica Wojtarowicz;Carolin Mogler;Iris Augustin;Michael Boutros;Christof Niehrs;Hellmut G Augustin - Developmental cell (2016)

引用本文的文献

1. Genomic evolution of cancer models: perils and opportunities. - Uri Ben-David;Rameen Beroukhim;Todd R Golub - Nature reviews. Cancer (2019)
2. The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. - Alexander M Frankell;SriGanesh Jammula;Xiaodun Li;Gianmarco Contino;Sarah Killcoyne;Sujath Abbas;Juliane Perner;Lawrence Bower;Ginny Devonshire;Emma Ococks;Nicola Grehan;James Mok;Maria O’Donovan;Shona MacRae;Matthew D Eldridge;Simon Tavaré; ;Rebecca C Fitzgerald - Nature genetics (2019)
3. Current Status of Patient-Derived Ovarian Cancer Models. - Yoshiaki Maru;Yoshitaka Hippo - Cells (2019)
4. Preclinical Modelling of PDA: Is Organoid the New Black? - Sabrina D’Agosto;Silvia Andreani;Aldo Scarpa;Vincenzo Corbo - International journal of molecular sciences (2019)
5. Establishment and characterization of patient-derived organoids from a young patient with cervical clear cell carcinoma. - Yoshiaki Maru;Naotake Tanaka;Keiko Ebisawa;Akiko Odaka;Takahiro Sugiyama;Makiko Itami;Yoshitaka Hippo - Cancer science (2019)
6. Xenograft and organoid model systems in cancer research. - Margit Bleijs;Marc van de Wetering;Hans Clevers;Jarno Drost - The EMBO journal (2019)
7. Disease modelling in human organoids. - Madeline A Lancaster;Meritxell Huch - Disease models & mechanisms (2019)
8. Biological Significance of Tumor Heterogeneity in Esophageal Squamous Cell Carcinoma. - Lehang Lin;De-Chen Lin - Cancers (2019)
9. In Silico Drug Prescription for Targeting Cancer Patient Heterogeneity and Prediction of Clinical Outcome. - Elena Piñeiro-Yáñez;María José Jiménez-Santos;Gonzalo Gómez-López;Fátima Al-Shahrour - Cancers (2019)
10. Context is everything: aneuploidy in cancer. - Uri Ben-David;Angelika Amon - Nature reviews. Genetics (2020)

… (180 更多 篇文献)

© 2025 MaltSci 麦伴科研 - 我们用人工智能技术重塑科研